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Platelet-activating factor (PAF) is a biologically
active phospholipid that activates platelets, leuko-
cytes, and other inflammatory cells. It is inactivated
by PAF acetylhydrolase (PAF-AH), a member of the
phospholipase A2 family. PAF-AH hydrolyzes PAF to
produce the biologically inactive product lyso-PAF,
and, thus, terminates its action. PAF-AH also pro-
tects low-density lipoprotein (LDL) against oxidative
modification,1 which is thought to be important in
preventing atherosclerosis. Approximately 4% of the
Japanese population does not possess this enzymatic
activity,2 whereas there have been no reports of PAF-
AH deficiency in Western countries. Recently, the
molecular structure of the human plasma PAF-AH
gene was determined,3 in which deficiency of this
enzyme is also identified to be a result of a single
point mutation (G994→T) in exon 9. The aim of this
study was to investigate the role of PAF-AH defi-
ciency in the etiology of atherosclerotic arterial
occlusive disease (AO) in the Japanese population.
MATERIALS AND METHODS
Subjects. Plasma PAF-AH genotype analysis was
done on blood samples from 104 patients with AO
who were treated at the Department of Surgery II of
Hamamatsu University Hospital. All of the patients
with AO were diagnosed through angiography and
underwent peripheral vascular surgery. Medical his-
tory was obtained including smoking habits and pres-
ence of hypertension, stroke, ischemic heart disease,
and diabetes. The presence of ischemic heart disease
was determined by a history of myocardial infarction
or angina and by abnormal results on an electrocar-
diogram. The distribution of the PAF-AH genotype
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was compared with that in 114 control subjects. The
control group was chosen from patients who visited
the hospital for gastrointestinal screening tests, such
as gastroscopy and colonoscopy, and who had no his-
tory of stroke or ischemic heart disease. The control
group consisted of individuals living in the same area
whose ages were matched with those of the patient
group. Most of the patients who underwent bypass
graft surgery are currently being periodically fol-
lowed up at our outpatient clinic. All subjects
enrolled in this study were Japanese and gave written,
informed consent. The Ethics Committee of the
Hamamatsu University School of Medicine approved
this study.
Genotype determination. Genomic DNA was
extracted from 2 mL of whole blood with a GenTLE
kit (Takara Biomedicals, Tokyo, Japan) according to
the manufacturer’s instructions. The genotype of plas-
ma PAF-AH was determined with an allele-specific
polymerase chain reaction (PCR), as previously
described.3 The sequences of the sense primer (sense
primer A) and three antisense primers (antisense
primers B, C, D) were as follows:
Sense primer A: 5´-CTATAAATTTATATCAT-
GCTT-3´
Antisense primer B: 5´-TTTACTATTCTCTTG-
CTTTAC-3´
Antisense primer C: 5´-TCACTAAGAGTCT-
GAATAAC-3´
Antisense primer D: 5´-TCACTAAGAGTCT-
GAATAAA-3´
Genotypes were designated as GG (normal), GT
(heterozygous), and TT (homozygous deficient).
Assay for plasma PAF-AH activity.  Venous
blood was collected into a tube containing EDTA
and centrifuged at ×2000g for 15 minutes at 4°C.
Plasma samples were stored at –70°C until the time
of assay. The activity of plasma PAF-AH was deter-
mined by the method described by Miwa et al.2
Statistical analysis. Data on age and plasma
PAF-AH activity are presented as means ± SD. A χ2
analysis was used to test deviations of genotype dis-
tribution. The frequencies of the mutant allele were
compared by calculating odds ratio. Patient charac-
teristics were also assessed by the χ2 test. Plasma
PAF-AH activity was compared by one-way analysis
of variance with the Scheffe test. A value of P < .05
was considered statistically significant.
RESULTS
Table I summarizes the prevalence of PAF-AH
deficiency in each group. There was no significant
difference in age or sex between the groups. The
prevalence of the GT + TT genotype was significant-
ly more frequent in patients with AO than in control
subjects (P = .038). The frequency of the mutant
allele in patients was 20%, which was significantly
higher than the 13% in control subjects (P = .035;
odds ratio = 1.59; 95% CI, 1.30-1.95).
Patient characteristics and other risk factors in
the 104 patients with AO are summarized in Table
II. Although there were no significant differences
among patients with GG and GT + TT genotype in
age, sex, smoking habits, hypertension, and dia-
betes, patients with the mutant allele tended to be
more likely to have overt evidence of prior stroke or
ischemic heart disease than patients with a normal
genotype. Table III shows the type of operations the
patients underwent. Aortoiliac artery bypass graft-
ing, iliofemoral artery bypass grafting, or femoro-
femoral crossover bypass grafting was performed for
aortoiliac occlusive disease. Infrainguinal bypass
grafting was performed for occlusion of the superfi-
cial femoral or popliteal artery. In patients with GG
genotype, only 17% of the group underwent a com-
bination of bypass grafting for aortoiliac occlusive
disease and infrainguinal bypass grafting, whereas
42% of the patients with GT + TT genotype under-
went the combined bypass graft operation.
The average value of plasma PAF-AH activity in
each group is shown in the Figure. Plasma PAF-AH
activity in GT heterozygotes was almost half of that
in subjects with the GG genotype. No PAF-AH
activity was detected in TT homozygotes. Plasma
PAF-AH activity was significantly higher in patients
with AO than in control subjects in normal geno-
type subgroups.
DISCUSSION
The current study provides the first evidence of
an association between the deficiency of plasma
PAF-AH and AO in the Japanese population. We
found that a single point mutation (G994→T) in
exon 9 was more frequent in patients with AO,
which suggests that patients with plasma PAF-AH
deficiency are more susceptible to arterial obstruc-
tion. Recently, it has been reported that the defi-
ciency of the enzyme is a risk factor for stroke and
coronary artery disease in Japanese people.4-6
Indeed, in the current study, patients with AO with
the mutant gene were more likely to have a history
of either stroke or ischemic heart disease than those
with normal genotypes. Moreover, higher percent-
ages of patients with AO with the mutant gene
underwent combined bypass graft operations for
aortoiliac and infrainguinal artery occlusion com-
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pared with patients with normal genotypes, which
suggested that the former group had experienced
more diffuse atherosclerotic changes. Therefore, this
mutation may play a crucial role in the pathogenesis
of atherosclerotic diseases in Japanese people.
The PAF is one of the most potent platelet ago-
nists that promote platelet aggregation. Activated
platelets also have cytotoxic effects on endothelial
cells, characterized by an increase of intracellular
Ca++ and a decrease of EDRF production.7
Therefore, a deficiency of plasma PAF-AH, which
fails to inactivate PAF, may make vessel walls vulner-
able to injury. In atherosclerosis, LDL, which may
be modified by oxidation, plays an important role by
injuring endothelium and underlying smooth mus-
cle cells by being trapped in an artery and being
internalized by means of the scavenger receptors on
the surface of macrophages.8 PAF-AH protects LDL
from oxidation and prevents internalization by
macrophages. This action may inhibit the initial
development of atherosclerosis.1,9 Therefore, the
deficiency of plasma PAF-AH may advance LDL-
associated atherosclerosis. However, the exact role
of plasma PAF-AH awaits studies of PAF-AH deple-
tion in animals, which has not yet been reported.
Moreover, further study is needed to assess the rela-
tionship between the level of plasma PAF-AH and
levels of cholesterol, lipoprotein, and triglycerides
among patients with AO.
In this study, we found only a 1.8% incidence of
homozygous deficiency in the control group, where-
as in a previously reported study, about 4% of
Japanese people lack enzymatic activity. There is
another mutation for plasma PAF-AH deficiency.
Yamada and Yokota10 identified the A1001→G
missence in exon 9, resulting in a Gln281→Arg sub-
stitution. The 4% of Japanese people lacking enzy-
matic activity in the study might be the result of
both mutations (G994→T and A1001→G). Although
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Table I. Plasma PAF-AH genotypes and alleles
Genotype (%)* Allele (%)†
Group (age) GG GT TT Total G T Total
Control (70.0 ± 6.3 y) 87 (76) 25 (22) 2 (2) 114 199 (87) 29 (13) 228
AO (71.3 ± 9.4 y) 66 (63) 34 (33) 4 (4) 104 166 (80) 42 (20) 208
*The prevalence of the mutation (GT and TT) was significantly higher in patients with AO than in control subjects (χ2 = 4.29; P < .05).
†The frequency of the mutant allele (T) was significantly higher in patients with AO than in control subjects (χ2 = 4.46; P < .05; odds
ratio 1.59; 95% CI, 1.30-1.95)
Table II. Patients’ characteristics (n = 104)
GG (n = 66) (%) GT + TT (n = 38) (%) P value*
Age (y) 71.7 ± 8.9 70.0 ± 10.4 .38
Sex (% male) 86 87 .95
Stroke 8 (12) 13 (34) .007
Ischemic heart disease 10 (15) 12 (31) .048
Hypertension† 34 (52) 17 (45) .51
Diabetes 14 (21) 8 (21) .98
Smoking 35 (53) 15 (40) .18
*By χ2 analysis.
†Patients’ blood pressure is 180/100 mm Hg or greater, or patients are taking antihypertensive medication.
Table III. Types of bypass graft operations
GG GT + TT
(n = 66) (n = 38)
(%) (%)
A-I, I-F, F-F bypass graft 40 (60) 10 (26)
A-I, I-F, F-F plus infrainguinal 11 (17) 16 (42)
bypass graft (combined bypass 
graft)
Infrainguinal bypass graft 15 (23) 12 (32)
Infrainguinal bypass graft includes femoropopliteal bypass graft,
femorotibial bypass graft, and popliteo-dorsalis pedis artery
bypass graft.
A-I, Aortoiliac artery bypass graft; F-F, femorofemoral crossover
bypass graft; I-F, iliofemoral artery bypass graft.
we did not assess the latter mutation in this study,
every individual with no plasma enzyme activity
showed TT homozygosity. Therefore, the discrepan-
cy of the incidence is likely to be attributable to
regional differences.
We demonstrated that plasma PAF-AH activity
in patients with AO was significantly higher than in
control subjects. Osterman et al11 also reported an
elevated capacity to degrade PAF in plasma from
patients with peripheral vascular disease.11 As for
other atherosclerotic diseases such as coronary
artery disease or stroke, some reports showed the
elevation of the enzymatic activity, whereas others
showed decrease of that activity in patients with such
atherosclerotic diseases.4,6,12-14 Currently, we have
no rational explanation for the elevation of plasma
PAF-AH activity in our patients. However, because
PAF and/or PAF-like phospholipid oxidative prod-
ucts are important mediators in the development of
atherosclerosis, higher levels of these substances may
serve as stimuli to increase the production of PAF-
AH by macrophages.15,16 Therefore, during the
development of atherosclerosis, the elevation of
PAF-AH may be one of the defense mechanisms
against atherosclerosis.
The cause of atherosclerosis is multifactorial. We
speculate that plasma PAF-AH deficiency is not a
definitive but a relative risk factor for susceptibility
to atherosclerosis, which is why many of the control
patients with the T allele did not have significant
atherosclerosis problems. In addition, the mutation
of other important genes, such as the endothelial
nitric oxide synthase gene or the angiotensin-
converting enzyme gene polymorphism, might be
involved in the pathogenesis of atherosclerosis.17,18
Therefore, further study is needed to investigate the
synergistic effect of the enzyme deficiency on ather-
osclerosis, in combination with other genetic and
environmental factors.
In summary, this study reports the first evidence
of an association between plasma PAF-AH deficiency
and a risk of AO in Japanese people. This study also
demonstrates the elevated plasma PAF-AH activity in
patients with AO. Our findings suggest that plasma
PAF-AH deficiency is important in the pathogenesis
of atherosclerosis. Further study is needed to clarify
the role of the enzyme in such diseases.
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